Zennova Pharma Group Wins the '2024 Innovation and Entrepreneurship Achievement Award' from CAST and China Haigui Alliance
Zennova
Specialty Drug Research and Development, Manufacturer
The 20th China HAIC Forum & 2024 China Returnee Entrepreneurship Confederation Annual Meeting Opens in Lanzhou on September 5Luo Hui, Member of the Party Leadership Group and Minister of International Cooperation Department of China Association for Science and Technology, Gansu ProvinceDeputy Provincial LeaderChina Association for Science and Technology (CAST)Chairman Zhang Shizhen, Hu Shengfa, President of China Haichuang United, and other leaders gave speeches.. This eventThere are fromRepresentatives from 20 countries' HaiZhi cooperation institutions and specially appointed experts,and all provinces and cities across ChinaNearly 300 representatives, including those from the China Association for Science and Technology (CAST), national academic societies, HaiZhi bases, representatives of the China Overseas Returnees Entrepreneurship Alliance, and well-known venture capital institutions.At the invitationAttend.
Mr. Guo Dahai, Founder and Chairman of Zennova, as a leading returnee entrepreneur in the pharmaceuticals industry, was awarded the "2024 Innovation and Entrepreneurship Achievement Award" by CAST & China Overseas Returnees Association at this conference, ranking first across the entire industry. Ms. Luo Hui, Member of the Party Leadership Group and Minister of International Cooperation at CAST, personally presented the award to Chairman Guo Dahai of Zennova. Chairman Guo Dahai was invited to deliver a speech at the conference as an awardee, in which he”There will be a time when we ride the wind and break the waves.”Shared his past entrepreneurial experiences on the topic, receiving a warm response at the conference.。
This award is a high recognition by the jury of Zennova's innovative technology and Mr. Guo Dahai's entrepreneurial achievements after reviewing numerous innovation and entrepreneurship projects nationwide. Zennova is based on the world-leading single-nanoparticle drug delivery platform Biocarrier, which has been developed through 20 years of original research.TMTechnology,突破了药物血脑屏障，且大幅提高不溶性药物分子生物利用度及生物安全性; 另一全球独创技术平台LiquiPlus®Awarded the only industry-wide recommended technology by the U.S. FDA for the microanalysis of insoluble drug molecules. Zennova focuses on ophthalmology, oncology, and cardiovascular fields, with research and development bases in New York and New Jersey, a dedicated production plant in Chicago, and a large-scale, full-dosage-form international pharmaceutical enterprise in Chengdu that integrates R&D, production, and sales. It has also established a research and development company in Suzhou Bio Bay. Zennova currently owns and has introduced more than X advanced drugs approved by the U.S. FDA.70Products, multiple products fill the gap in China's pharmaceutical market. Self-developed new drug pipeline11Zennova Pharmaceuticals Group produces a range of drugs, all of which have reached internationally leading technical levels. All drugs produced by Zennova comply with the quality standards of the US FDA, EU EMA, and China. The company has successfully expanded its market.29Pharmaceutical sales channels in various countries and regions, signing product cooperation production and sales agreements with multiple international pharmaceutical companies. Zennova Pharmaceuticals GroupInternationally Leading Pharmaceutical R&D、Integrated companies for production and global sales have alsoWon the first place in the biopharmaceutical category of the "Golden Rooster Lake National Entrepreneurship Competition" (formerly known as the "National Thousand Talents Program Entrepreneurship Competition") in China.
Mr. Guo Dahai, the founder of Zennova, is a well-known leading figure in the internationalization of China's pharmaceutical industry, with a successful track record of serial entrepreneurship. In 2013, he was awarded the "Key Global Chinese Entrepreneur Award" by the State Council. He founded and led the successful overseas pharmaceutical company PuraCap Pharmaceuticals, as well as Renfu Puke Pharmaceuticals, one of China’s top ten pharmaceutical exporters, which has now grown into the world's largest softgel capsule formulation pharmaceutical enterprise.
Zennova Pharma Group is an innovative international pharmaceutical company group with three strategic focuses: Made in China, global research and development, and global market. It concentrates on four therapeutic areas: ophthalmology, viruses, cardiovascular, and oncology. Zennova Pharma Group currently has R&D bases in New York and New Jersey, USA, a contract manufacturing plant in Chicago, USA, and an all dosage forms international formulation center that integrates R&D, production, and sales in Chengdu, China. The company owns Liquipuls, a globally original technology researched and developed in the USA for 20 years.®+BiocarrierTMNew Drug Development Technology Platform. Zennova Pharmaceuticals Group always adheres to the core value of "Commitment to Life, Scaling Pharmaceutical Peaks" (Innovation for better medicine), achieving high-level production and high-quality export of medicines, promoting the internationalization of Chinese pharmaceuticals, and making good and innovative medicines for the health of humanity.
